ENTA News and Press, Enanta Pharmaceuticals Inc. From 03/27/20

TherapeuticsMD Provides Business Updates, Suspends Guidance Due to COVID 19 TherapeuticsMD ( TXMD ) announced important updates about its business operations including introducing cost reduction initiatives. The company also stated that it has decided to suspend its guidance for FY 2020....

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported an update on its clinical trial activities in response to the COVID-19 pandemic. In order to ensure the safety ...

Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...

Citing its know-how in antiviral development and its attractive valuation, Baird has upgraded to Enanta Pharmaceuticals ( ENTA -5.3% ) to Outperform with a $60 (56% upside) price target. It believes that the company is well-positioned to push a viable candidate for COVID-19 over the finish...

Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Neutral rating and $45 (107% upside) price target at Goldman Sachs. More news on: Arrowhead Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, , Read more...

The following healthcare companies have announces recent actions related to COVID-19: More news on: OPKO Health, Inc., Luminex Corporation, Enanta Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Company Leverages Proven Antiviral and Respiratory Expertise to Evaluate Existing Compounds and New Approaches for Treating the Novel Coronavirus Disease COVID-19 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule dru...

The European Commission approves an eight-week treatment regimen (formerly 12 weeks) for AbbVie's (NYSE: ABBV ) Maviret (glecaprevir/pibrentasvir) for treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. More news on: AbbVie Inc....

MAVIRET now available in the EU as an 8-week treatment option for treatment-naïve, chronic hepatitis C virus (HCV) patients without cirrhosis or with compensated cirrhosis, regardless of genotype* European Commission’s decision makes MAVIRET the only 8-week treatment reg...

In my previous article regarding NASH disease and the potential winners of the first wave drugs, I made a comparison of efficacy of the late stage drug candidates which have better chances to be first in the market of NASH. For those who are interested, please click here . In this article, ...